Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, University of South Australia, Adelaide, Australia.
Br J Clin Pharmacol. 2010 Aug;70(2):252-7. doi: 10.1111/j.1365-2125.2010.03694.x.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * Up to 21% of adverse drug event related hospital admissions are due to drug interactions. Clinical significance of drug interactions varies. * Studies which only identified drug interactions of potentially major clinical significance found lower prevalence, of between 2 and 16%. * Prevalence of drug interactions defined 'potentially hazardous' has had limited study, with no publications identified for the Australian population. WHAT THIS STUDY ADDS * In the study population of 287 074, 1.5% of subjects were dispensed potentially hazardous interacting drug pairs. * However, limited to populations on specific medicines, it was found that for patients dispensed verapamil, methotrexate, amiodarone, lithium, warfarin, cyclosporin and itraconazole, potentially hazardous interactions occurred at a rate greater than 5%. * These patients should be the focus of medication review programmes to avoid potentially serious adverse drug events. BACKGROUND Up to 21% of adverse drug event-related hospital admissions are due to drug interactions. Clinical significance of drug interactions varies, and drug interactions defined 'potentially hazardous' are more likely to contribute to morbidity and mortality. AIM The aim of this study was to assess the prevalence of potentially hazardous drug interactions in an elderly Australian veteran population. METHODS This study assessed the prevalence of potentially hazardous drug interactions, where hazardous was defined in three or more international drug interaction references, using Repatriation Pharmaceutical Benefits Scheme pharmacy claims data. Analysis was limited to patients who received regular concurrent dispensings of potentially hazardous interacting medicines. RESULTS Of the 287 074 subjects included in the study, 1.5% were dispensed potentially hazardous interacting drug pairs. For patients dispensed cyclosporin, concomitant use of a statin was common (47%); as was statin use with those dispensed itraconazole (31%). Of those dispensed methotrexate, 24% also received a non-steroidal anti-inflammatory drug; of those on lithium, 18% also received an ACE inhibitor or angiotensin 2 receptor blocker; of those on warfarin, 7.2% and 5.9% were co-dispensed an non-steroidal anti-inflammatory drugs or antiplatelets respectively; for those on verapamil, 5.3% were co-dispensed a beta-blocker, while for those on amiodarone 6.2% were co-dispensed digoxin. CONCLUSIONS Overall prevalence of potentially serious drug interactions appears to be low in the Australian veteran population. However, patients taking cyclosporine, itraconazole, methotrexate, lithium, warfarin, verapamil and amiodarone appear to be most at risk and their medicine use should be regularly reviewed to prevent potentially hazardous drug interactions.
已知信息 * 多达 21%的药物不良反应相关住院事件是由药物相互作用引起的。药物相互作用的临床意义各不相同。* 仅发现具有潜在重大临床意义的药物相互作用的研究发现,其发生率较低,为 2%至 16%之间。* 对定义为“潜在危险”的药物相互作用的研究有限,没有发现针对澳大利亚人群的出版物。* 本研究的新增信息 * 在 287074 名研究对象中,有 1.5%的受试者同时使用了潜在危险的相互作用药物组合。* 然而,仅限于特定药物的人群,发现接受维拉帕米、甲氨蝶呤、胺碘酮、锂、华法林、环孢素和伊曲康唑的患者,其潜在危险的相互作用发生率大于 5%。* 这些患者应成为药物审查计划的重点,以避免潜在的严重药物不良反应。背景信息 多达 21%的药物不良反应相关住院事件是由药物相互作用引起的。药物相互作用的临床意义各不相同,并且被定义为“潜在危险”的药物相互作用更有可能导致发病率和死亡率增加。目的 本研究旨在评估老年澳大利亚退伍军人人群中潜在危险药物相互作用的发生率。方法 本研究使用退伍军人医药福利计划(Repatriation Pharmaceutical Benefits Scheme)的药房理赔数据,使用三种或更多国际药物相互作用参考资料,评估了潜在危险药物相互作用的发生率,其中危险被定义为三种或更多国际药物相互作用参考资料。分析仅限于同时接受潜在危险相互作用药物常规同时配药的患者。结果 在纳入研究的 287074 名受试者中,有 1.5%的受试者同时使用了潜在危险的相互作用药物组合。接受环孢素治疗的患者中,同时使用他汀类药物的情况很常见(47%);同时使用伊曲康唑的患者也很常见(31%)。接受甲氨蝶呤治疗的患者中,有 24%同时使用了非甾体抗炎药;接受锂治疗的患者中,有 18%同时使用了 ACE 抑制剂或血管紧张素 2 受体阻滞剂;接受华法林治疗的患者中,分别有 7.2%和 5.9%同时使用了非甾体抗炎药或抗血小板药物;接受维拉帕米治疗的患者中,有 5.3%同时使用了β受体阻滞剂,而接受胺碘酮治疗的患者中,有 6.2%同时使用了地高辛。结论 在澳大利亚退伍军人人群中,潜在严重药物相互作用的总体发生率似乎较低。然而,接受环孢素、伊曲康唑、甲氨蝶呤、锂、华法林、维拉帕米和胺碘酮治疗的患者风险最大,应定期审查其用药情况,以防止潜在的危险药物相互作用。